NCT05194787 TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease
| NCT ID | NCT05194787 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Tasmania |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2021-03-05 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2021-03-05 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. Similar to screening for pre-diabetes and carcinoma in situ, it is important to detect AD at the preclinical stage in order to offer early interventions before the pathology progresses to the irrerversible degenerative stage. In the study, research will develop a new scalable test (TAS Test) by combining two innovative ideas: hand-movement tests to detect pre-AD \>10 years before cognitive symptoms begin; and computer vision so people can "self-test" online using home computers. This unique approach builds on recent discoveries that hand-movement patterns change in pre-AD. The research team will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, and combine this with machine learning of overall motor-cognitive performance. The project team has access to 3 well-phenotyped cohorts, \>10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. The research team will develop a TAS Test algorithm to classify hand-movement and cognitive test data for pre-AD risk (p-taua181 levels) and determine TAS Test's precision to prospectively predict 5-year risks of cognitive decline and AD.
Eligibility Criteria
Inclusion Criteria: \> 50years old Exclusion Criteria: established diagnosis of dementia
Contact & Investigator
Prof Vickers, PhD DSc
STUDY DIRECTOR
University of Tasmania
Frequently Asked Questions
Who can join the NCT05194787 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05194787 currently recruiting?
Yes, NCT05194787 is actively recruiting participants. Contact the research team at Jane.Alty@utas.edu.au for enrollment information.
Where is the NCT05194787 trial being conducted?
This trial is being conducted at Hobart, Australia.
Who is sponsoring the NCT05194787 clinical trial?
NCT05194787 is sponsored by University of Tasmania. The principal investigator is Prof Vickers, PhD DSc at University of Tasmania. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.